HIV

An autopsy-based study examined long-term trends in HIV-related mortality among individuals living with the disease in New York City.

New and emerging strategies in the management of HIV

Top news of the day from across the health care landscape.

HIV-related immunosuppression may contribute to an elevated risk of cancer-related morbidity in elderly patients with the disease.

A study in the Bukoba municipality of Tanzania has suggested that scaling up HIV testing, improving linkages to HIV care, and strengthening retention of antiretroviral therapy interventions can help increase viral load suppression (VLS).

It is prudent for pharmacists to stay current with these therapies and prevention strategies, as they are well-positioned to educate and support patients in their illness.

A study by the CDC has made several findings around injection practices and sexual behaviors among HIV-positive persons who inject drugs.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Data from a pair of phase 3 trials were recently presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

The TANGO study assessed whether adults maintained viral suppression for at least 6 months after switching to the the dolutegravir/lamivudine combination.

Individuals with persistent HIV in the cells of their cerebrospinal fluid are more likely to experience neurocognitive impairment.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.

Top news of the day from across the health care landscape.

Prequalification tells global funders and Ministries of Health that the product meets global standards of quality, safety, and performance.

CDc11+ dendritic cells are the first to interact with HIV and transmit the virus to other cells in the body.

This funding is part of an effort to provide technical assistance to enhance efforts to end the HIV epidemic.

Fewer than 40% of people have ever had a HIV test, and less than 30% of people in the United States most at risk of acquiring HIV were tested in the past year.

In addition to offering on-site free and fast HIV testing, counselors from local agencies will answer questions about HIV prevention and treatment options, including PrEP, at certain Walgreens stores across the country.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

In the statement, USPSTF officials noted that people who take PrEP should continue to use condoms and practice other behaviors to reduce their risk of other sexually transmitted infections.

Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population.

Many different strategies to achieve sustained virologic remission in HIV are being evaluated.

Case reports of sustained HIV-1 remission, new drug approvals, and resistance testing provide patients with potential novel therapy approaches.

Study could lead to advances in HIV vaccine development because functional immunity to HIV is needed from a vaccine.

Top news of the day from across the health care landscape.

Patients must be counseled about the risk of acute or chronic liver steatosis associated with all prescription and over the counter medications.

Effective treatment with ART has increased the life span of people living with HIV, but they remain at risk for chronic diseases.